1-6-2014

Renal recovery

Stuart L. Goldstein  
*Cincinnati Children's Hospital Medical Center*

Lakhmir S. Chawla  
*George Washington University*

Claudio Ronco  
*San Bortolo Hospital, Vicenza, Italy*

John A. Kellum  
*University of Pittsburgh*

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_anesth_facpubs

Part of the Anesthesia and Analgesia Commons

Recommended Citation

Abstract

Acute kidney injury (AKI) research in the past decade has mostly focused upon development of a standard AKI definition, validation of early novel biomarkers to predict AKI prior to serum creatinine rise and predict AKI severity, and assessment of aspects of renal replacement therapies and their impact on survival. Given the independent association between AKI and mortality in the acute phase, such focus makes imminent sense. More recently, the recognition that AKI is associated with subsequent development of chronic kidney disease and end-stage renal disease, with the attendant increase in mortality, has led to interest in the clinical epidemiology and the mechanistic understanding of renal recovery after an AKI episode in critically ill patients. We review the current knowledge surrounding renal recovery after an AKI episode, including renal replacement therapy initiation timing and modality impact, biomarker assessment and mechanistic targets to guide potential future clinical trials.

Background

The field of acute kidney injury (AKI) in the critically ill patient population has been subject to a significant research focus over the past decade. Hallmarks of this research progress include development and validation of standardized multidimensional AKI definitions [1,2], which help assessment of AKI outcomes, discovery of novel biomarkers to detect AKI development and predict AKI severity earlier [3], and prospective randomized trials enabling assessment of potentially modifiable aspects of AKI supportive care, namely the timing and intensity of renal replacement therapy delivery [4,5]. The realization that patients are dying from, and not just with, AKI [6] has driven the effort to alter the course of AKI. By reducing rates of ‘kidney attack’ [7,8], thereby preventing or at least mitigating AKI, patient mortality and morbidity should likewise be lessened. A natural extension of ‘peri-AKI’ epidemiological research would expand the focus to patients who survive an AKI episode, and a reassessment of the long-term consequences of AKI. The fact that episodes of AKI are associated with more rapid progression to chronic kidney disease (CKD) in adult patients is a relatively recent observation [9]; the 2009 United States Renal Data System Report revealed that adults with an AKI episode during hospitalization have an approximately 10-fold greater risk of progressing to end-stage renal disease than patients who did not experience AKI [10]. Similar observations were also reported around the same time for cardiac surgery patients [11]. The goals of this review on renal recovery after AKI are to 1) provide a state of the art description of our current understanding of the epidemiology of AKI survivors, 2) describe the evolution of novel biomarkers in the AKI to CKD field and 3) describe potential risk factors for renal recovery versus non-recovery in AKI survivors.

Renal recovery: the definition

Serum creatinine-based definitions

None of the advancements in AKI research would have occurred without development and validation of the first standardized multi-dimensional AKI definition, known as the RIFLE criteria (Risk, Injury, Failure, Loss, End-stage kidney disease) [1], and its subsequent recalibrations, pediatric RIFLE (pRIFLE) [12], the Acute Kidney Injury Network [2] and Kidney Disease Improving Global Outcomes (KDIGO) criteria [13]. Likewise, a standard definition of renal recovery is essential to provide an accurate account of post-AKI epidemiology. The Acute Dialysis Quality Initiative II work group provided the first such definition when they proposed the empiric RIFLE criteria, as the ‘Loss’ and ‘End-stage kidney disease’ strata (‘L’ and ‘E’) contained both estimated glomerular filtration rate (GFR) and time components in their metrics. Loss is defined as persistent complete loss of kidney function requiring dialysis, and End-stage kidney disease is defined as the loss of kidney function requiring dialysis for at least 90 days. Recovery is considered the clinical reappearance of GFR to 70% of the baseline GFR value.
function for greater than 4 weeks, and End-stage kidney
disease is defined as complete loss of kidney function at
3 months after AKI development. The KDIGO AKI
Workgroup proposed a refinement with the somewhat
less severe concept of ‘acute kidney disease’ (AKD).
AKD, defined as a GFR <60 ml/minute/1.73 m² or evi-
dence of structural kidney damage for less than
3 months, provides an operationally integrated bridge
between AKI and CKD. The AKD concept, which incor-
porates the concept of partial renal recovery, should be
used to raise awareness and engender the necessary clin-
ical mechanisms to follow AKI survivors for progression
to CKD, which has been recently highlighted as a missed
opportunity for adequate transitions of care [14].

Prospective AKI trials in the critically ill have mostly
focused upon patients who receive acute renal replace-
ment therapy (RRT), since they are at the highest risk
for mortality and RRT is one of the few aspects of the
AKI episode that is modifiable. A more temporally prox-
imal definition of renal recovery was utilized in the Vet-
ers Affairs/National Institutes of Health Acute Renal
Failure Trial Network (ATN) trial; patients with a 6 hour
creatinine clearance >20 ml/minute were trialed off RRT,
whereas patients with a creatinine clearance <12 ml/mi-
nute had RRT continued [4]. Thus, at the current time,
the definition of renal recovery depends upon the time
frame of interest, as depicted in Figure 1.

The report from the 2011 NIDDK Workshop on Clin-
cial Trial Design [15] recently proposed a composite
endpoint of death, dialysis provision and incomplete
renal recovery at 28 or 60 days. This concept had already
been used in the evaluation of plasma neutrophil
gelatinase-associated lipocalin (NGAL) as a predictor of
renal recovery defined by the composite of mortality,
persistence of RIFLE-F or need for RRT [16] and was
subsequently operationalized as Major Adverse Kidney
Events at Day 30 in a study of novel AKI biomarker pre-
diction of AKI and outcomes [17]. Future prospective
interventional trials aimed at promoting renal recovery
should consider incorporating at least one of these defi-
nitions as an outcome. An important consequence of
these composite endpoints is that the issue of competing
risk between persistent renal dysfunction, RRT and death
is obviated by combining these outcomes into a single
endpoint. In addition, they are perhaps more patient-
centered since kidneys that recover in patients that die
will be valued less by these patients.

GFR estimation reflects late functional changes, which
are inherently delayed since the kidneys contain the
in-nate ability to maintain function by hyperfiltration and
compensatory hypertrophy of the remaining healthy
nephrons, irrespective of the etiology for the kidney
damage. This nephron adaptation allows for continued
clearance of plasma solutes, so that serum creatinine in-
creases only after about 50% of nephrons have been lost.
Thus, it is important to note that even if creatinine-
based GFR returns to normal, there may be a potential
loss of renal reserve, so that repeated episodes of AKI
may unmask clinically detectable CKD.

There are alternatives to serum creatinine-based defi-
nitions of renal recovery, which include timed urine col-
lections for creatinine clearance measurement, direct

Figure 1 Time periods for renal recovery based on various study endpoints in the published literature. AKD, acute kidney disease [13];
AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RIFLE-E, end-stage of of Risk, Injury, Failure, Loss,
End-stage kidney disease criteria [1]; RIFLE-R, loss stage of Risk, Injury, Failure, Loss, End-stage kidney disease criteria; RRT, renal
replacement therapy.
GFR assessment by radionuclide clearance and GFR estimation using Cystatin C, a molecule that has ideal properties of clearance by filtration with a serum concentration that is not dependent on muscle mass. Going forward, epidemiological research studies should employ these methods to reduce the issues with sole reliance on serum creatinine.

**Classic biomarker injury-based definitions**

While extensive research has been expended to identify novel biomarkers to identify acute kidney damage earlier and predict AKI severity [18,19], widespread outcomes studies of specific biomarkers for the early detection of progression from AKI to CKD do not exist. Thus, at present, in addition to the estimation of GFR noted above, measurement of proteinuria or microalbuminuria, which are extrapolated from the diabetic nephropathy progression model, have been hallmarks of CKD assessment [20]. Proteinuria, albuminuria and microalbuminuria have been studied extensively in both adult and pediatric cross-sectional studies of AKI survivors [21-25]. Recent reports in adult populations have supported the use of proteinuria for prediction of adverse outcomes in CKD [20,26,27]. However, significant structural damage has typically already occurred before proteinuria is measureable, and kidney function decline has usually already commenced at the onset of microalbuminuria [28-30]. Furthermore, the predictive value of microalbuminuria has been questioned, since a large proportion of diabetic patients exhibit spontaneous resolution, and only a minority progress to overt proteinuria [31].

**Prediction of renal recovery**

One set of current tools for potentially predicting renal recovery is encompassed in clinical severity of illness (SOI) scores. While these may seem attractive options initially, it is important to remember that SOI scores are used to characterize and stratify adult and pediatric critical illness [32]. The initial SOI systems were developed to benchmark, or compare, critical care units against one another, to monitor resource use, evaluate therapies, and improve quality assessment. They were not intended to predict SOI in individual patients but, rather, to group patients together in strata of illness, which would allow group-wide mortality or SOI prediction. As an example, Uchino and colleagues [33] tested two general illness severity scores (Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment (SOFA)), and four AKI-specific severity scores in 1,742 patients as part of the BEST Kidney Study. None of these scoring systems tested had a high level of discrimination or calibration to predict outcome for AKI patients. If systems do not perform well to predict AKI-associated mortality, it is no wonder that prediction of renal recovery has remained elusive as well [34]. Although factors such as advanced age, male gender, presence of sepsis/septic shock, hypotension, respiratory failure, use of mechanical ventilation, presence of oliguria, and high serum bilirubin, low serum creatinine, and using vasoactive substances are risk factors for AKI [35], we know far less about the clinical determinants of renal recovery. In a small study, a subset (n = 76) of the ATN study cohort [4], Srirawat and colleagues found that age and underlying chronic disease predicted non-recovery of renal function (area under the curve (AUC) 0.74) following provision of RRT for AKI [16]. Determinants of renal recovery may be influenced by etiology of AKI. The same authors studied recovery following severe AKI (RIFLE-F) in patients with community-acquired pneumonia and found that a model composed of age, creatinine on the first day of RIFLE-F, pneumonia severity index on admission, and maximum non-renal SOFA score yielded an AUC of 0.78 [36]. Some recent work has demonstrated promise for clinical prediction for renal recovery with more specific markers. A systematic review of patients with hemolytic uremic syndrome revealed that renal replacement therapy provision and central nervous system involvement increased risk for end-stage renal disease [37], although rates of renal recovery were not directly addressed. A recent assessment of AKI to stage 4 CKD progression in the US Veterans population developed and then validated three models to predict CKD risk, with increasing AKI severity by RIFLE score and in-hospital hypoalbuminemia providing the strongest prediction [38]. Of note, each increase in RIFLE score was associated with an adjusted odds ratio of 4.43 for development of stage 4 CKD, which was higher than any other covariate except the need for RRT. Although these models require validation in other cohorts and should be tested longitudinally in a systematic assessment of patients at risk for AKI, they provide some clues as to which patients should be targeted for close follow-up and potentially therapeutic trials to slow CKD progression.

Although oliguria (urine output less than 400 ml/day) is a common event in the ICU and urine flow is one of the diagnostic and staging criteria for AKI, only a few studies have focused on the role of urine output as a prognostic renal biomarker. Oliguric patients without change in serum creatinine concentrations demonstrated increased mortality rates and dialysis requirements similar to patients with serum creatinine change-based AKI [39]. A post hoc analysis from the BEST kidney study revealed that the urine output area under the receiver operating characteristic curve for successful discontinuation of continuous RRT (CRRT) was 0.85, although it fell to 0.67 when diuretics were used. Urine output
cutoffs of 436 ml/day and 2,330 ml/day for patients without and with diuretics, respectively, had the highest accuracy [40].

Recently, some studies have begun to assess the ability of novel biomarkers to predict renal recovery and/or progression to CKD. NGAL has been extensively studied in the field of AKI [41]. In the late phase of AKI, NGAL is believed to play a role as a growth and differentiation factor for restoring tubular epithelial function with the assistance of siderophore-iron complexes. However, most previous studies have tested plasma/urine NGAL as a marker for early diagnosis of AKI; only a few studies have examined plasma/urine NGAL as a prognostic marker of clinical outcome, mostly with mortality and hospital length of stay as endpoints. In fact, a systematic review demonstrated similar mortality rates and length of stay for patients with 'NGAL-positive: creatinine-negative' AKI versus 'NGAL-negative: creatinine-positive' AKI [42].

Two studies (also mentioned above) have assessed NGAL as a predictor of renal recovery [16,36]. Plasma NGAL was assessed in patients with community-acquired pneumonia on the first day they experienced severe AKI (defined as RIFLE-F), and recovery was defined as being alive and neither requiring RRT during hospitalization nor having a persistent RIFLE-F classification at hospital discharge [36]. The investigators found that elevated plasma NGAL levels were associated with renal non-recovery with a 17% increase in predicting renal non-recovery. The second study, the Biological Markers of Recovery for the Kidney study [16], was conducted as an ancillary to the ATN study [4]. Urine samples were collected on days 1, 7, and 14 from 76 patients who developed AKI and received RRT in the ICU. For predicting recovery, decreasing urinary NGAL and urinary hepatocyte growth factor in the first 14 days was associated with greater odds of renal recovery.

Interestingly, animal models of AKI-to-CKD transition identify NGAL, as well as another novel AKI biomarker, Kidney injury molecule-1 (KIM-1), as two of the most upregulated genes and proteins in the kidney, revealing a possible role for these proteins as biomarkers [43]. Furthermore, studies on urinary NGAL and KIM-1 in other renal diseases demonstrate higher NGAL concentrations are associated with more rapid progression of CKD [44-49]. Coupling the animal data with the human data noted provides evidence that novel biomarkers can serve as early markers of ongoing renal injury, even in the setting of AKI. The clinical impact is potentially great in the setting of AKI, for even if a patient is undergoing dialysis, therapies directed at mitigating ongoing injury may have a role in AKI treatment and CKD prevention.

Promoting renal recovery
Mechanisms of recovery
The kidney has a tremendous capacity for repair following different types of AKI. Interestingly, regeneration and repair mechanisms lead to the expression of many different developmental signaling pathways [50]. Proximal tubular epithelial cells are particularly susceptible to AKI as they are positioned closest to the glomeruli (and are thus first to ‘see’ various endogenous and exogenous toxins) [51] as well as having the highest metabolic rate (and are thus susceptible to ischemia and metabolic toxins). Once injured, tubular epithelial cells can re-differentiate after an initial phase of dedifferentiation and proliferation, thus replacing cells that are lost to necrosis, apoptosis, or simply shedding from the basement membrane during injury [52]. This ‘healthy repair process’ can go awry at various stages, leading to fibrosis and CKD. Various mechanisms have been implicated in controlling the repair process [53], many of which may represent drug targets. Recently, Notch signaling, a cell-cell communication mechanism that regulates development, tissue homeostasis and repair, has been identified to play a potential role in repair and regeneration after AKI [54]. Generally absent in the mature kidney, Notch is reactivated after AKI, and could be responsible for cellular differentiation, proliferation and repair [55]. This notion is supported by studies from various laboratories that independently observed a linkage between increased expression of Notch2 and its target Hes1 and increased proliferation of renal tubular epithelial cells in the setting of various insults [56-58].

Therapies
While a number of medications have been studied to prevent AKI development and severity, including diuretics, adenosine A1 receptor antagonist and dopamine receptor alpha1-specific agonists, the results have been nearly uniformly negative [59-61], although fenoldopam has been shown to improve urine output and NGAL elevation in children after cardiac surgery in a pilot study [62,63]. Thus, it logically follows that these agents may not be helpful to promote renal recovery. New therapies aimed more specifically at mechanisms of renal fibrosis and maladaptive repair are under development, some with promising pre-clinical results.

Two aspects of RRT provision have recently been assessed for their potential impact on renal recovery: fluid overload at the time of RRT initiation and RRT modality. Each of these factors is important, since they represent potentially modifiable treatment decisions available today to improve outcomes. The association between increasing degrees of fluid overload at RRT initiation as well as the negative impact of fluid overload in critically ill patients with and without AKI has been well
documented in the pediatric and adult critical care literature. Multiple multicenter studies demonstrate increased mortality in patients with greater than 10 to 20% ICU fluid accumulation at CRRT initiation [64-66]. A single center study demonstrated that initiation of RRT at less than 10% fluid overload was associated with improved renal recovery, with each 1% of fluid overload carrying a 3% reduction in renal recovery rates [67]. The potential explanation for this association posits that fluid overload increases the risk of intra-abdominal compartment syndrome and increases renal venous pressure, leading to renal interstitial edema with resultant decreased glomerular filtration, distorted tissue architecture, and impaired tissue perfusion.

The two recent, large, well conducted, randomized, multicenter trials, ATN [4] and RENAL [5], which did not demonstrate a benefit of higher RRT intensity on survival or renal recovery, have provided high-quality data to assess the impact of RRT modality on renal recovery, since the two studies had very different rates of renal recovery. Overall, the cohorts were closely matched; however, recovery of renal function by day 28 was substantially better in RENAL versus ATN (87% versus 55%).

What differences between the two studies could account for this difference in renal recovery? Although the chronological time to start of treatment was shorter in RENAL compared to ATN (2.1 versus 6.7 days), the BUN concentration at the start of therapy (another surrogate for timing) was nearly identical. Another difference between the two trials that could have accounted for the differences in outcomes was the exclusive use of CRRT as the initial mode of RRT in the RENAL trial compared to a strategy that allocated patients to CRRT only if they were hemodynamically unstable (cardiovascular SOFA score >2) in the ATN trial, while more stable patients received intermittent hemodialysis.

A very recent meta-analysis of RRT modality and renal recovery lends significant credence to the proposition that CRRT is associated with improved renal recovery compared to intermittent RRT (IRRT) [68]. Ultimately, 23 total studies (randomized controlled n = 7, observational n = 16), comprising 3,977 AKI survivors, fulfilled criteria for the comparison of CRRT to IRRT. Pooled averages from the studies demonstrated that patients receiving IRRT initially were generally less severely ill, with lower rates of mechanical ventilation, vasopressor administration and CKD. The overall relative risk (RR) from all studies for dialysis dependence was higher for IRRT patients (RR 1.73, 95% confidence interval (CI) 1.35 to 2.20). However, this association was not observed in the pooled average of randomized controlled trials (RR 1.15, 95% CI 0.78 to 1.68), and only held true in the pooled averages for the observational trials (RR 1.99, 95% CI 1.53 to 2.59). The authors note that the randomized controlled trials only included small studies (combined patient total of 472 AKI survivors) and enrolled less severely ill patients. Furthermore, most randomized controlled trials have only included patients who could receive either modality, excluding those deemed too unstable for standard IRRT.

Conclusion
Recovery of renal function following an episode of AKI is far from certain and a growing body of evidence suggests that progression of underlying CKD or even development of de novo CKD may occur following an episode of AKI. Patients who fail to recover will have a significantly shorter life-span and succumb to a number of morbidities. The underlying cellular and physiologic mechanisms that drive outcomes after AKI are poorly characterized. Epidemiologic evidence strongly suggests that advanced age is the most significant risk factor for non-recovery of renal function but this may merely reflect a diminished renal functional reserve in this population. Since there is a potential independent risk conferred by multiple AKI episodes on CKD progression [9], the clinical focus at present must continue to be on avoiding subsequent AKI episodes in the critically ill.

Abbreviations
AKD: Acute kidney disease; AKI: Acute kidney injury; ATN: Acute renal failure trial network; AUC: Area under the curve; CI: Confidence interval; CKD: Chronic kidney disease; CRRT: Continuous renal replacement therapy; GFR: Glomerular filtration rate; IRRT: Intermittent renal replacement therapy; KDIGO: Kidney disease improving global outcomes; KIM-1: Kidney injury molecule-1; NGAL: Neutrophil gelatinase-associated lipocalin; RIFLE: Risk, injury, failure, loss, end-stage kidney disease; RR: Relative risk; RRT: Renal replacement therapy; SOFA: Sequential organ failure assessment; SOI: Severity of illness.

Competing interests
The authors declare that they have no competing interests.

Author details
1Center for Acute Care Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 2Department of Anesthesiology and Critical Care Medicine, George Washington University Medical Center, Washington DC Division of Renal Diseases and Hypertension, Washington, DC 20037, USA. 3Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA. 4Department of Nephrology, Dialysis and Transplantation, International Renal Research Institute, San Bortolo Hospital, Vicenza 36100, Italy. 5Center for Critical Care Nephrology, CRISMA (Clinical Research, Investigation, and Systems Modeling of Acute Illness) Center, Pittsburgh, PA 15213, USA. 6Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.

Published: 06 Jan 2014

References


